Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Schreiber

Showing results (1-10 of 82) with videos related to

Pageof 9
Sort By:
Seminars in Immunology|November 4, 2008
Tumor-specific immune responsesHans Schreiber
The Journal of Experimental Medicine|February 3, 2019
Fibroblasts: Dangerous travel companionsHans Schreiber
Current Opinion in Immunology|April 1, 2015
Editorial overview: tumour immunologyHans Schreiber, Phil Greenberg
Cancer Immunity|June 7, 2005
Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cellsMichael T Spiotto, Hans Schreiber
Cancer Research|January 11, 2014
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--letterDavid C Binder, Hans Schreiber
Science (New York, N.Y.)|November 6, 2010
Cancer. Awakening immunityHans Schreiber, Donald A Rowley
Oncoimmunology|February 25, 2014
High-affinity peptide-based anticancer vaccination to overcome resistance to immunostimulatory antibodiesDavid C Binder, Hans Schreiber
Journal of Immunological Methods|May 6, 2006
Floxed reporter genes: Flow-cytometric selection of clonable cells expressing high levels of a target gene after tamoxifen-regulated Cre-loxP recombinationMichael T Spiotto, Hans Schreiber
Science (New York, N.Y.)|January 12, 2008
Cancer. Quo vadis, specificity?Hans Schreiber, Donald A Rowley
Seminars in Immunology|August 8, 2008
Specificity in cancer immunotherapyAndrea Schietinger, Mary Philip, Hans Schreiber
Pageof 9

Showing results (1-10 of 82) with videos related to

Sort By:
Pageof 9
Seminars in Immunology|November 4, 2008
Tumor-specific immune responsesHans Schreiber
The Journal of Experimental Medicine|February 3, 2019
Fibroblasts: Dangerous travel companionsHans Schreiber
Current Opinion in Immunology|April 1, 2015
Editorial overview: tumour immunologyHans Schreiber, Phil Greenberg
Cancer Immunity|June 7, 2005
Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cellsMichael T Spiotto, Hans Schreiber
Cancer Research|January 11, 2014
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--letterDavid C Binder, Hans Schreiber
Science (New York, N.Y.)|November 6, 2010
Cancer. Awakening immunityHans Schreiber, Donald A Rowley
Oncoimmunology|February 25, 2014
High-affinity peptide-based anticancer vaccination to overcome resistance to immunostimulatory antibodiesDavid C Binder, Hans Schreiber
Journal of Immunological Methods|May 6, 2006
Floxed reporter genes: Flow-cytometric selection of clonable cells expressing high levels of a target gene after tamoxifen-regulated Cre-loxP recombinationMichael T Spiotto, Hans Schreiber
Science (New York, N.Y.)|January 12, 2008
Cancer. Quo vadis, specificity?Hans Schreiber, Donald A Rowley
Seminars in Immunology|August 8, 2008
Specificity in cancer immunotherapyAndrea Schietinger, Mary Philip, Hans Schreiber
Pageof 9